Sumitomo Chemical Co., Ltd. TSE:4005

Sumitomo Chemical : Summary of Consolidated Financial Results for Fiscal Year 2025

Published

Source: MarketScreener

Key Figures of Consolidated Financial Results for FY2025

May 14, 2026 Sumitomo Chemical Co., Ltd.
  1. Financial Summary (IFRS) (Billions of yen)

    FY2025

    FY2024

    Variance

    FY2026

    (Forecast)

    Variance

    Sales revenue

    2,328.5

    2,606.3

    (277.8)

    2,360.0

    31.5

    Core operating income

    208.4

    140.5

    67.9

    215.0

    6.6

    Operating income

    151.7

    193.0

    (41.3)

    177.0

    25.3

    Net income attributable to owners of the parent

    60.9

    38.6

    22.4

    70.0

    9.1

    Basic earnings per share

    ¥ 37.16

    ¥ 23.59

    ¥ 13.57

    ¥ 42.40

    ¥ 5.24

    Return on equity

    6.4%

    4.1%

    2.3%

    6.8%

    0.4%

    Cash dividends per share

    ¥ 13.50

    ¥ 9.00

    ¥ 4.50

    ¥ 16.00

    ¥ 2.50

    Dividend payout ratio

    36.3%

    38.2%

    (1.9)%

    37.7%

    1.4%

    Exchange rate (yen/$)

    150.67

    152.62

    -

    155.00

    -

    Naphtha price (yen/kl)

    65,200

    75,600

    -

    92,000

    -

    *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

  2. Sales Revenue / Core Operating Income by Reporting Segment (IFRS) (Billions of yen)

    FY2025

    FY2024 Variance

    ( FY2026 ) Variance Forecast

    Agro & Life Solutions

    Sales revenue

    519.3

    540.2

    (21.0)

    560.0

    40.7

    Core operating

    income

    56.3

    55.0

    1.4

    65.0

    8.7

    ICT & Mobility Solutions

    Sales revenue

    574.2

    607.0

    (32.8)

    590.0

    15.8

    Core operating

    income

    53.0

    70.6

    (17.5)

    55.0

    2.0

    Advanced Medical Solutions

    Sales revenue

    58.6

    62.1

    (3.5)

    60.0

    1.4

    Core operating

    income

    2.8

    4.0

    (1.1)

    3.0

    0.2

    Essential & Green Materials

    Sales revenue

    678.8

    899.0

    (220.2)

    560.0

    (118.8)

    Core operating

    income

    14.4

    (58.5)

    72.9

    20.0

    5.6

    Sumitomo Pharma

    Sales revenue

    451.9

    398.0

    53.9

    540.0

    88.1

    Core operating

    income

    108.4

    35.3

    73.1

    94.0

    (14.4)

    Others

    Sales revenue

    45.8

    99.9

    (54.1)

    50.0

    4.2

    Core operating

    income

    4.4

    66.9

    (62.5)

    4.0

    (0.4)

    Adjustments

    Sales revenue

    -

    -

    -

    -

    -

    Core operating

    income

    (31.1)

    (32.7)

    1.6

    (26.0)

    5.1

    Total

    Sales revenue

    2,328.5

    2,606.3

    (277.8)

    2,360.0

    31.5

    Core operating

    income

    208.4

    140.5

    67.9

    215.0

    6.6

  3. Summary of Consolidated Statement of Income (IFRS)

    (Billions of yen)

    FY2025

    FY2024

    Variance

    Variance Ratio

    Sales revenue

    2,328.5

    2,606.3

    (277.8)

    (10.7)%

    Core operating income

    208.4

    140.5

    67.9

    48.3%

    of which equity-method investments

    (43.3)

    (62.9)

    19.7

    -

    Total non-recurring items (breakdown below)

    (56.6)

    52.5

    (109.1)

    -

    Impairment losses

    (34.6)

    (26.3)

    (8.3)

    -

    Restructuring costs

    (26.6)

    (23.6)

    (3.0)

    -

    Gains on sales of property,

    plant and equipment, and intangible assets

    1.2

    14.3

    (13.1)

    -

    Share of profit of investments accounted for using the equity method (non-recurring factors)

    -

    83.6

    (83.6)

    -

    Gains on fair value measurement of the residual interest

    -

    9.4

    (9.4)

    -

    Others

    3.4

    (4.9)

    8.3

    -

    Operating income

    151.7

    193.0

    (41.3)

    (21.4)%

    Finance income/expenses (breakdown below)

    (35.7)

    0.7

    (13.6)

    -(22.8)

    (134.9)

    99.3

    -

    Loss on foreign currency transactions including

    (10.9)

    11.7

    -

    gain (loss) on derivatives

    Loss on valuation of investment securities

    -

    (13.6)

    -

    Loss on debt waiver for a loan

    (109.8)

    109.8

    -

    Others

    (14.2)

    (8.6)

    -

    Income before taxes

    116.1

    58.1

    58.0

    99.8%

    Income tax expenses

    (0.7)

    (15.4)

    14.7

    -

    Net income

    115.4

    42.7

    72.7

    170.3%

    Net (income) loss attributable to non-controlling interests

    (54.5)

    (4.1)

    (50.4)

    -

    Net income attributable to owners of the parent

    60.9

    38.6

    22.4

    57.9%

    ROE

    6.4%

    4.1%

    Exchange rate (yen/$)

    150.67

    152.62

    Naphtha price (yen/kl)

    65,200

    75,600

    Overseas sales revenue ratio

    71.0%

    69.9%

  4. Summary of Consolidated Statement of Financial Position (IFRS)

    (Billions of yen)

    31-Mar-26

    31-Mar-25 Variance

    31-Mar-26

    31-Mar-25 Variance

    Current assets

    1,507.7

    1,583.1

    (75.4)

    Liabilities

    2,168.4

    2,365.4

    (197.0)

    Cash and cash

    equivalents

    208.6

    209.8

    (1.2)

    Trade and other payables

    464.4

    488.1

    (23.7)

    Trade and other

    receivables

    608.7

    593.8

    14.8

    Interest-bearing liabilities

    1,151.5

    1,286.1

    (134.7)

    Inventories

    595.5

    625.2

    (29.8)

    Others

    552.5

    591.1

    (38.6)

    Others

    95.0

    154.2

    (59.2)

    Equity

    1,236.7

    1,074.4

    162.3

    Non-current assets

    1,897.3

    1,856.7

    40.7

    Shareholders' equity

    744.9

    722.3

    22.6

    Property, plant and

    equipment

    770.7

    759.3

    11.4

    Other components of

    equity

    263.8

    178.5

    85.3

    Goodwill and intangible

    assets

    501.0

    497.1

    3.9

    Non-controlling interests

    228.0

    173.6

    54.4

    Others

    625.6

    600.3

    25.3

    Total

    3,405.0

    3,439.8

    (34.7)

    Total

    3,405.0

    3,439.8

    (34.7)

    Ratio of equity attributable to

    owners of the parent to total assets

    29.6%

    26.2%

    3.4%

    D/E ratio (times)

    0.93

    1.20

    (0.27)

  5. Summary of Consolidated Statement of Cash Flows (IFRS)

    (Billions of yen)

    FY2025

    FY2024 Variance

    ( FY2026 ) Variance Forecast

    Cash flows from operating activities

    234.8

    233.0

    1.7

    210.0

    (24.8)

    Cash flows from investing activities

    (74.8)

    85.2

    (160.1)

    (150.0)

    (75.2)

    Free cash flows

    159.9

    318.3

    (158.3)

    60.0

    (99.9)

    Cash flows from financing activities

    (199.1)

    (300.8)

    101.7

    0.0

    199.1

    Others

    15.7

    (6.8)

    22.5

    0.0

    (15.7)

    Increase (decrease) in cash and cash equivalents

    (23.5)

    10.7

    (34.1)

    60.0

    83.5

    Cash and cash equivalents at the end of the period

    208.6

    209.8

    (1.2)

    268.6

    60.0

    (Billions of yen)

    FY2025

    FY2024

    Variance

    FY2026

    (Forecast)

    Variance

    Capital expenditures

    121.6

    131.7

    (10.2)

    119.0

    (2.6)

    Depreciation and amortization expenses

    121.1

    131.6

    (10.5)

    121.0

    (0.1)

    Research and development expenses

    144.7

    145.2

    (0.5)

    161.0

    16.3

    Interest-bearing liabilities at the end of the period

    1,151.5

    1,286.1

    (134.7)

    1,120.0

    (31.5)

    Net interest expenses

    (21.7)

    (12.9)

    (8.9)

    (24.0)

    (2.3)

    Number of employees at the end of the period

    27,491

    29,279

    (1,788)

    27,700

    209

    Number of consolidated subsidiaries and equity method investees

    175

    195

    (20)

    174

    (1)

    Of which: subsidiaries

    152

    168

    (16)

    150

    (2)

  6. Other Data (IFRS)


May 14, 2026

Summary of Consolidated Financial Results for Fiscal Year 2025 (Under IFRS)

Company name: Sumitomo Chemical Co., Ltd. Listing: Tokyo Stock Exchange Securities code: 4005

URL: https://www.sumitomo-chem.co.jp/english/ Representative: Nobuaki Mito, Representative Director & President

Inquiries: Toshihiro Yamauchi, Managing Executive Officer, General Manager, Corporate Communications Dept. Telephone: +81-3-5201-0200

Scheduled date of annual general meeting of shareholders: June 24, 2026 Scheduled date to commence dividend payments: June 3, 2026

Scheduled date to file annual securities report: June 22, 2026 Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes (for institutional investors and analysts)

(All amounts are rounded to the nearest million yen.)

  1. Consolidated Financial Results for Fiscal Year 2025 (April 1, 2025 to March 31, 2026)
    1. Consolidated Operating Results (Percentages indicate year-on-year changes.)

      Sales revenue

      Core operating income

      Operating income

      Net income

      Net income attributable to owners of the parent

      Total comprehensive income

      Millions of yen

      %

      Millions of yen

      %

      Millions of yen

      %

      Millions of yen

      %

      Millions of yen

      %

      Millions of yen

      %

      -

      -

      FY2025

      2,328,515

      (10.7)

      208,376

      48.3

      151,744

      (21.4)

      115,402

      170.3

      60,947

      57.9

      187,881

      FY2024

      2,606,281

      6.5

      140,519

      -

      193,033

      -

      42,688

      -

      38,591

      -

      (54,622)

      Basic earnings per share

      Diluted earnings per share

      Return on equity attributable to owners of the parent

      Ratio of income before taxes to total assets

      Ratio of core operating income to sales revenue

      FY2025

      Yen

      37.16

      Yen

      37.15

      %

      6.4

      %

      3.4

      %

      8.9

      FY2024

      23.59

      23.58

      4.1

      1.6

      5.4

      Reference: Share of profit (loss) of investments accounted for using the equity method FY2025: ¥ (43,271)million FY2024: ¥ 20,639 million

      Income before taxes

      FY2025: ¥ 116,068 million FY2024: ¥ 58,093 million

      *Core operating income is a gain and loss concept that reflects recurring earning capacity by deducting gains and losses incurred by non-recurring factors from operating income, which includes the share of profits or losses from investments accounted for using the equity method.

    2. Consolidated Financial Position

      Total assets

      Total equity

      Equity attributable to owners of the parent

      Ratio of equity attributable to owners of the parent to total assets

      Equity attributable to owners of the parent per share

      As of

      Millions of yen

      Millions of yen

      Millions of yen

      %

      Yen

      March 31, 2026

      3,405,041

      1,236,673

      1,008,644

      29.6

      610.78

      March 31, 2025

      3,439,784

      1,074,415

      900,790

      26.2

      550.37

    3. Consolidated Cash Flows

    Cash flows from operating activities

    Cash flows from investing activities

    Cash flows from financing activities

    Cash and cash equivalents at the end of the period

    FY2025

    Millions of yen

    234,759

    Millions of yen

    (74,821)

    Millions of yen

    (199,068)

    Millions of yen

    208,589

    FY2024

    233,027

    85,229

    (300,778)

    209,838

  2. Dividends

    Dividends per share

    Total dividends

    Dividend payout ratio (Consolidated)

    Ratio of dividends to equity attributable to owners of the parent

    (Consolidated)

    Q1

    end

    Q2

    end

    Q3

    end

    Year-end

    Annual

    FY2024 FY2025

    Yen

    Yen

    Yen

    Yen

    Yen

    Millions of yen

    %

    %

    -

    -

    3.00

    6.00

    -

    -

    6.00

    7.50

    9.00

    13.50

    14,730

    22,210

    38.2

    36.3

    1.6

    2.3

    FY2026

    (Forecast)

    -

    8.00

    -

    8.00

    16.00

    37.7

  3. Consolidated Financial Forecasts for Fiscal Year 2026 (April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

Sales revenue

Core operating income

Operating income

Net income attributable to owners of the parent

Basic earnings per share

Millions of

yen

%

Millions of

yen

%

Millions of

yen

%

Millions of

yen

%

Yen

First-half of FY2026

-

-

-

-

-

-

-

-

-

Full-year of FY2026

2,360,000

1.4

215,000

3.2

177,000

16.6

70,000

14.9

42.40

*The consolidated financial forecast for the first-half of FY2026 is not disclosed due to prediction difficulties.

Notes:

  1. Changes in significant subsidiaries during the period: Yes Newly consolidated: －

    Excluded: 2 companies (XUYOU Electronic Materials (Wuxi) Co., Ltd.) (Sumitomo Pharma UK Holdings, Ltd.)

  2. Changes in accounting policies and changes in accounting estimates

    1. Changes in accounting policies required by IFRS: None

    2. Changes in accounting policies due to other reasons: None

    3. Changes in accounting estimates: None